Argent BioPharma (RGT), formerly MGC Pharmaceuticals, has sold the global commercialisation rights of its leading epilepsy drug, CannEpil, in order to clear a sizable chunk of its debt.
Chill Brands [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CHLL.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Chill Brands published a ‘trading update’ to investors this morning, revealing growth in a number of key sales channels, but stopping short of providing any solid revenue figures.
MGC Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals announced this week that it has now secured ‘binding commitments’ for US$7.9m in investment, which the company says will be enough to fund its business plan over the next 12-months.
MGC Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals, which became the first cannabis company to list on the London Stock Exchange (LSE) in 2021, informed investors this week that due to adverse market conditions it ‘finds itself at a critical financial juncture’.
MGC Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals announced the closure of its share purchase plan (SPP) this week, seeing the company successfully raise a further A$834k (£426k).
MGC Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals released a flurry of updates over the last week, announcing plans to launch a A$2.7m share purchase plan for its Australian investors, just weeks after conditionally raising a further £700,000.
Cantourage [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”HIGH.F” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] German-listed cannabis distributor Cantourage informed investors this week that it expects to see ‘double digit’ sales growth and ‘a break-even result at EBITDA level’ in 2023.
Cellular Goods [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CBX.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Cellular Goods has issued a long-awaited update to investors regarding its recent acquisition of carbon sequestration company King Tide Carbon (KTC).
Ananda Developments Aquis Stock Exchange-listed Ananda Developments has seen its stock jump by nearly 20% over the last week following the announcement that its MRX1 CBD oil is on track to launch commercially this month.
